Roivant Sciences (ROIV) Insider Allen Sells $437K of Stock
On June 30, 2026, insider Gold Daniel Allen sold 12,380 shares of Roivant Sciences for $436,766.
Reviewed by automated data checks against the source filing. How we make and check alerts
Gold Daniel Allen sold 12,380 shares of Roivant Sciences Ltd. ($ROIV) at an average price of $35.28, worth about $436,766.40, on June 30, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $ROIV is up 2.6% after 1 week, down 2.5% after 1 month and down 5.3% to date (from the $35.39 close on Jun 30, 2026).
ROIV
Roivant Sciences Ltd.
Key Points
- Gold Daniel Allen sold 12,380 shares of Roivant Sciences Ltd. for about $436,766 on June 30, 2026.
- The stock is currently trading at $35.39, below its 52-week high of $42.50.
- Analysts maintain a strong buy recommendation with a consensus target mean price of $47.79.
Get $ROIV trade alerts by text
We text you when insiders, Congress or big funds trade $ROIV. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Roivant Sciences Ltd. alert may contain errors. Disclosures
Insider Buying and Selling at Roivant Sciences Ltd.
Gold Daniel Allen, an insider at Roivant Sciences Ltd. (NasdaqGS: ROIV), sold 12,380 shares on June 30, 2026. The transaction was valued at approximately $436,766, with shares trading at an average price of $35.28. This sale reflects a strategic choice at a time when the stock trades at $35.39, below its recent highs.
Recent Insider Activity
Just days prior to Allen's sale, Mayukh Sukhatme, President & CIO, executed two significant trades. On June 25, he sold 500,000 shares for about $17.07 million, after exercising stock options. Earlier the same day, he also purchased 500,000 shares at $3.85, demonstrating active management of his holdings. Eric Venker, President & Immunovant CEO, also made notable trades, including selling 200,000 shares worth $6.63 million and buying 200,000 shares for $770,000 on June 24. CFO Richard Pulik and Chief Accounting Officer Jennifer Humes also sold shares on June 20.
The Stock's Context
Roivant Sciences' shares are currently priced at $35.39, slightly below its 50-day moving average of $36.26. The stock has seen a noticeable range over the past year, bouncing between $14.50 and $42.50. The recent trading activity, including Allen's sale, occurs as the company prepares for its next earnings report on November 9, 2026.
Analysts Set New Price Targets
Analysts have a generally positive outlook on Roivant Sciences. Wolfe Research recently downgraded the stock to a Peer Perform rating on October 12, 2026. However, firms like Stifel and TD Cowen maintain a Buy rating with price targets of $51 and $55, respectively. The consensus price target among 12 analysts stands at $47.79, suggesting confidence in the company's future performance despite recent stock fluctuations.
What Roivant Sciences Ltd. Does
Roivant Sciences Ltd., based in London, is focused on developing and commercializing innovative biopharmaceuticals. Its work centers on various clinical-stage candidates that target significant health conditions. This insider activity highlights ongoing engagement by key executives in managing their stakes as the company navigates its strategic direction.
What to Watch at Roivant Sciences Ltd.
Investors should keep an eye on the upcoming earnings report scheduled for November 9, 2026. This event may provide further insights into the company's performance and direction, alongside the recent insider transactions. Remember, this Form 4 filing reflects past transactions and may not represent current positions.
Related Filing Alerts
Source: Gold Daniel Allen's Form 4 filing on $ROIV (Jun 30, 2026). Find the original filing: ROIV Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts